The American Journal of Managed Care

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”

EHA 2026 highlights included practice-changing immunotherapy data in relapsed/refractory multiple myeloma and high-risk pediatric B-cell ALL, plus insights on childhood cancer predisposition.
The American Journal of Managed Care

Phase 1 UCART22 Trial Shows Promising Activity in R/R B-Cell ALL: Nitin Jain, MD

Phase 1 BALLI-01 trial results showed promising UCART22 activity in R/R B-cell ALL, with higher remission rates after a ...
The American Journal of Managed Care

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

Tebipenem pivoxil becomes the only FDA-approved oral carbapenem for complicated UTIs/pyelonephritis in adults lacking viable ...
The American Journal of Managed Care

SUNMO: ADC Plus Bispecific Yields Double PFS of Chemotherapy at 2 Years in R/R LBCL, With Lowest CRS Rate Seen

Prolonged follow-up showed superior PFS with mosun-pola versus R-GemOx in the overall SUNMO population (HR, 0.41) alongside ...
The American Journal of Managed Care

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

Implementation barriers remain largely programmatic, requiring integrated HIV testing, adherence support, STI services, and ...